3상모집 중단 (진행 중)

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy

연구 개요

The goal of this clinical study is to see if sacituzumab govitecan-hziy (SG) can improve life spans of people with HR+/HER2- metastatic breast cancer and their tumor does not grow or spread when compared to currently available standard treatments, such as paclitaxel, nab-paclitaxel or capecitabine. The primary objective is to compare the effect of SG relative to the treatment of physician's choice (TPC) on progression-free survival (PFS).

스폰서: 리드: 길리어드
적응증: Locally Advanced or Unresectable Metastatic Breast Cancer, Stage IV Breast Cancer
중재: Sacituzumab Govitecan-hziy, Paclitaxel, Nab-paclitaxel, Capecitabine
목표 등록: 654명
시작일: 2023-05-08
완료(예정): 2028-04-01
등록번호: NCT05840211 · ClinicalTrials.gov ↗

BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.